What is Cardiotrack?
Cardiotrack operates as a sophisticated healthcare platform, adeptly merging telemedicine capabilities with a suite of proprietary and third-party IoT-enabled diagnostic devices. This integration facilitates a streamlined and efficient medical testing experience for users. At its core is the Ethos platform, designed to amplify tele-health efficacy by cultivating a comprehensive diagnostic ecosystem. The company's specialized offerings include advanced portable ECG units and the Cardiac Risk Assessment (CRA) test, providing cutting-edge solutions for cardiac diagnostics. Cardiotrack's services are tailored to a diverse clientele, encompassing physicians, insurers, re-insurers, and corporate health providers, positioning it as a key player in digital health innovation.
How much funding has Cardiotrack raised?
Cardiotrack has raised a total of $2M across 1 funding round:
Series A
$2M
Series A (2024): $2M, investors not publicly disclosed
What's next for Cardiotrack?
The recent major strategic investment signals a strong validation of Cardiotrack's business model and its potential for significant growth and market penetration. This infusion of capital is expected to accelerate the development and deployment of its integrated telemedicine and diagnostic device solutions. The company is likely to focus on expanding its reach within the enterprise healthcare sector, forging new partnerships with insurers and corporate clients, and further enhancing its Ethos platform. Strategic expansion into new geographical markets and the continuous innovation of its diagnostic hardware, particularly in cardiac monitoring, are also probable next steps, solidifying its position as a leader in the digital health and remote patient monitoring space.
See full Cardiotrack company page
